SML3211
Mogrol
≥98% (HPLC)
Synonym(s):
Mogrol, (3β,9β,10α,11α,24R)-9-Methyl-19-norlanost-5-ene-3,11,24,25-tetrol
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C30H52O4
CAS Number:
Molecular Weight:
476.73
MDL number:
UNSPSC Code:
12352107
NACRES:
NA.77
Recommended Products
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
Looking for similar products? Visit Product Comparison Guide
Biochem/physiol Actions
Mogrol is an aglycone of mogrosides from Siraitia grosvenorii that exhibits neuroprotective and anticancer activities. It induces apoptosis in K562 leukemia cells through suppression of ERK1/2 and STAT3 pathways. Mogrol appears to ameliorate the memory impairment caused by Aβ1-42 in mice. Mogrol increases AMPK activity in hepatocytes and suppresses adipocyte differentiation in 3T3-L1 cells.
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Gangling Chen et al.
The Journal of pharmacy and pharmacology, 71(5), 869-877 (2018-12-27)
Cognitive impairment is the main character of Alzheimer's disease (AD). This study mainly focused on whether mogrol, a tetracyclic triterpenoids compound of Siraitia grosvenorii Swingle, can ameliorate the memory impairment induced by Aβ1-42 . Memory impairment mice model was made
Naoki Harada et al.
PloS one, 11(9), e0162252-e0162252 (2016-09-02)
This study investigated the effects of mogrol, an aglycone of mogrosides from Siraitia grosvenorii, on adipogenesis in 3T3-L1 preadipocytes. Mogrol, but not mogrosides, suppressed triglyceride accumulation by affecting early (days 0-2) and late (days 4-8), but not middle (days 2-4)
Can Liu et al.
American journal of cancer research, 5(4), 1308-1318 (2015-06-24)
Unlike solid tumors, the primary strategy for leukemia treatment is chemotherapy. However, leukemia chemotherapy is associated with adverse drug effects and drug resistance. Therefore, it is imperative to identify novel agents that effectively treat leukemia while minimizing adverse effects. The
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service